Bio-Path Holdings Inc. - BPTH Company Long-Term Liabilities

Bio-Path Holdings Inc. - graphic logo of issuer BPTH

Bio-Path Holdings (BPTH) minimizes scientific risks by employing unique RNA methods in the development of leukemia and tumor treatments. The business model relies on external contractors for formula synthesis and testing, which eliminates the need for the firm to incur manufacturing plant costs. This chart of current market quotes shows debt at 0.00. Strict FDA oversight regarding molecule safety is slowing the expansion of this therapeutic niche.

BPTH (biopathholdings.com) Company Long-Term Debt history from 07/04/2022 to 03/01/2025

Summary analytical data breakdowns for Bio-Path (BPTH)

- price and consensus price forecast:
Share Price biopathholdings.com|BPTH - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Bio-Path Holdings|BPTH - Enterprise Value
- book capitalization data:
Net Asset Value per Share Bio-Path Holdings|BPTH - Company Book Value|Market Value to Book Value biopathholdings.com|BPTH - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Bio-Path Holdings|BPTH - Long-Term Debt to Capital|Short-Term Debt to Equity Bio-Path Holdings, Inc|BPTH - Company Debts|Debt to Book Capitalization Ratio Bio-Path Holdings|BPTH - Company Long-Term Debt|Short-Term Debt Bio-Path Holdings
Analysis of all company metrics:biopathholdings.com (BPTH)
Original product of Bio-Path Holdings, Inc

Bio-Path Holdings (BPTH) develops anti-tumor RNA drugs while adhering to strict bioethics and ESG standards. An analysis of the corporation's long-term loans and borrowings allows for an assessment of the sustainability of this scientific model. This metric aggregates all obligations with a maturity of more than one year, measuring the issuer's financial autonomy. A reduction in the debt load confirms a margin of safety, although it limits the effect of financial leverage. This determines the actual investment reliability of the asset.

Direct competitors

Company Long-Term Indebtedness tgtherapeutics.com TGTX|ACLX: Company Long-Term Debts|IRON - Company Long-Term Liabilities|Company Long-Term Debts SNDX|KURA (Kura) - Long-Term Debt|ADCT - Company Long-Term Debt|Company Long-Term Loans and Borrowings Foghorn (FHTX)|Vor Biopharma (VOR) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings nkartatx.com (NKTX)|Company Long-Term Debts Coeptis Therapeutics, Inc. COEP|Actinium Corp - Company Long-Term Debt|ESLA - Company Long-Term Debt|CASI: Company Long-Term Debt|Company Long-Term Debt MRKR|INAB (IN8bio Inc.) - Long-Term Debt|Company Long-Term Debt ERNA (Eterna Therapeutics, Inc.)|Long-Term Debt GT Biopharma Corporation|Company Long-Term Debts Aptose Biosciences Inc. APTO|Company Long-Term Indebtedness meipharma.com (MEIP)|Company Long-Term Debts Vincerx Pharma VINC